Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The Senior Vice President of Medicines Discovery and Development at GlaxoSmithKline discusses the rationale for the recent evolution of the company's research and development strategy.
For more than 50 years, warfarin has been the standard of care for long-term anticoagulation therapy in the United States, but now the FDA has approved the first oral anticoagulant that could replace it.